作者
Dóra Mosztbacher, Lilla Hanák, Nelli Farkas, Andrea Szentesi, Alexandra Mikó, Judit Bajor, Patrícia Sarlós, József Czimmer, Áron Vincze, Péter Jenő Hegyi, Bálint Erőss, Tamás Takács, László Czakó, Balázs Csaba Németh, Ferenc Izbéki, Adrienn Halász, László Gajdán, József Hamvas, Mária Papp, Ildikó Földi, Krisztina Eszter Fehér, Márta Varga, Klára Csefkó, Imola Török, Hunor Pál Farkas, Artautas Mickevicius, Elena Ramirez Maldonado, Ville Sallinen, János Novák, Ali Tüzün Ince, Shamil Galeev, Barnabás Bod, János Sümegi, Petr Pencik, Zsolt Dubravcsik, Dóra Illés, Szilárd Gódi, Balázs Kui, Katalin Márta, Dániel Pécsi, Péter Varjú, Zsolt Szakács, Erika Darvasi, Andrea Párniczky, Péter Hegyi, Hungarian Pancreatic Study Group
发表日期
2020/6/1
期刊
Pancreatology
卷号
20
期号
4
页码范围
608-616
出版商
Elsevier
简介
Background
Hypertriglyceridemia is the third most common cause of acute pancreatitis (AP). It has been shown that hypertriglyceridemia aggravates the severity and related complications of AP; however, detailed analyses of large cohorts are contradictory. Our aim was to investigate the dose-dependent effect of hypertriglyceridemia on AP.
Methods
AP patients over 18 years old who underwent triglyceride measurement within the initial three days were included into our cohort analysis from a prospective international, multicenter AP registry operated by the Hungarian Pancreatic Study Group. Data on 716 AP cases were analyzed. Six groups were created based on the highest triglyceride level (<1.7 mmol/l, 1.7–2.19 mmol/l, 2.2–5.59 mmol/l, 5.6–11.29 mmol/l, 11.3–22.59 mmol/l, ≥22.6 mmol/l).
Results
Hypertriglyceridemia (≥1.7 mmol/l) presented in 30.6% of the patients and was significantly and dose-dependently …
学术搜索中的文章
D Mosztbacher, L Hanák, N Farkas, A Szentesi, A Mikó… - Pancreatology, 2020